Abstract
Osteosarcoma is one of the most prevalent primary bone malignancies in children and adolescents. Magnetic resonance imaging (MRI) is a critical tool for providing anatomical information about the tumor and surrounding main blood vessels. This study evaluates the prognostic significance of radiological vascular involvement according to pre-treatment MRI in 482 patients with Enneking IIB osteosarcoma. Univariate and multivariable analyses identified vascular involvement as an independent risk factor for overall survival (OS) and event-free survival (EFS). A new subtyping system (Types I, II, and III) based on the relationship between the tumor, the surrounding reactive area, and main blood vessels was found to predict prognosis and provide directive information for selecting appropriate surgical procedures.
Introduction
Osteosarcoma is the most common primary bone malignancy in children and adolescents. Most patients are classified as "Enneking IIB" (high-grade, extracompartmental tumors), yet this group exhibits highly variable clinical outcomes. While MRI is standard for visualizing tumor anatomy, its potential to provide a standardized, pre-treatment prognostic marker based on vascular involvement has remained under-explored. This study seeks to bridge this gap by quantifying the relationship between tumors and adjacent neurovascular bundles to help surgeons decide between limb-salvaging procedures and amputation before treatment begins.
Methods and Materials
The researchers conducted a retrospective study of 482 patients younger than 50 years old with Enneking IIB primary osteosarcoma of the extremities treated between 2005 and 2015. The majority of tumors were located in the distal femur (65.1%) and proximal tibia (24.3%).
Patients followed a standardized treatment protocol involving neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy.
The study focused on two key MRI measurements to assess vascular involvement:
- NBR (Nearest to Blood vessel to Reactive zone): The shortest distance from the center of the main blood vessels to the margin of the peritumoral reactive area (edema/inflammation).
- NBT (Nearest to Blood vessel to Tumor): The shortest distance from the center of the main blood vessels to the margin of the actual tumor lesion.
Based on these measurements, three subtypes were proposed:
- Type I: Vessels are clear of the reactive area (NBR > 0, NBT > 0).
- Type II: Vessels are involved in the reactive area but not the tumor lesion (NBR = 0, NBT > 0).
- Type III: Vessels are radiologically involved with the tumor lesion itself (NBR = 0, NBT = 0).
Key Results
Radiological vascular involvement (RVI) was identified as a significant independent risk factor for both OS (HR = 2.32) and EFS (HR = 1.81). The proposed subtyping system showed stark differences in survival outcomes:
- 5-Year Overall Survival (OS): Type I (81.6%), Type II (67.1%), and Type III (44.8%).
- 5-Year Event-Free Survival (EFS): Type I (60.2%), Type II (46.7%), and Type III (30.2%).
- Amputation Rates: Only 4.3% of Type I patients required amputation, compared to a staggering 87.5% of Type III patients.
The study highlights that the surrounding "reactive zone"—which MRI identifies as edema—often contains satellite tumor cells. If blood vessels pass through this zone (Type II), the prognosis drops significantly compared to when they are clear (Type I). For Type III patients, the high amputation rate suggests that limb-salvage is rarely viable or safe.
Discussion and Conclusion
Vascular involvement according to radiological findings from pretreatment MRI is an independent risk factor for cumulative OS and EFS in patients with Enneking IIB primary osteosarcoma. This new subtyping provides a clear clinical roadmap for selecting appropriate surgical procedures for individual patients.
While the study is limited by its retrospective nature and single-center data, it underscores the importance of the peritumoral reactive zone in prognosis. Future research should focus on prospective trials to confirm if this MRI subtyping can be used to tailor chemotherapy intensity or specific surgical margins.
Summary updated